Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 244

1.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

2.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

3.

The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout.

Szekanecz Z, Szamosi S, Kovács GE, Kocsis E, Benkő S.

Arch Biochem Biophys. 2019 Jan 30. pii: S0003-9861(18)30755-0. doi: 10.1016/j.abb.2019.01.031. [Epub ahead of print] Review.

PMID:
30710503
4.

Peripheral Lymphocyte Multidrug Resistance Activity as a Predictive Tool of Biological Therapeutic Response in Rheumatoid Arthritis.

Toldi G, Batel P, Baráth S, Szerémy P, Apjok A, Filkor K, Szántó S, Szűcs G, Szamosi S, Häupl T, Grützkau A, Szekanecz Z.

J Rheumatol. 2019 Feb 1. pii: jrheum.180793. doi: 10.3899/jrheum.180793. [Epub ahead of print]

PMID:
30709954
5.

Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis.

Gulácsi L, Zrubka Z, Brodszky V, Rencz F, Alten R, Szekanecz Z, Péntek M.

Adv Ther. 2019 Jan 12. doi: 10.1007/s12325-018-0869-8. [Epub ahead of print]

PMID:
30637590
6.

Common mechanisms and holistic care in atherosclerosis and osteoporosis.

Szekanecz Z, Raterman HG, Pethő Z, Lems WF.

Arthritis Res Ther. 2019 Jan 10;21(1):15. doi: 10.1186/s13075-018-1805-7. Review.

7.

Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis.

Balogh E, Pusztai A, Hamar A, Végh E, Szamosi S, Kerekes G, McCormick J, Biniecka M, Szántó S, Szűcs G, Nagy Z, Fearon U, Veale DJ, Szekanecz Z.

Clin Immunol. 2019 Feb;199:47-51. doi: 10.1016/j.clim.2018.12.011. Epub 2018 Dec 10.

PMID:
30543922
8.

[Recent advances in gout: pathogenesis, diagnosis, comorbidities, treatment].

Soós B, Szamosi S, Benkő S, Paragh G, Szekanecz Z.

Orv Hetil. 2018 Oct;159(40):1625-1636. doi: 10.1556/650.2018.31270. Review. Hungarian.

PMID:
30277413
9.

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G; whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis.

Ann Rheum Dis. 2018 Dec;77(12):1705-1709. doi: 10.1136/annrheumdis-2018-213687. Epub 2018 Sep 7.

PMID:
30194273
10.

2018 update of the EULAR recommendations for the management of hand osteoarthritis.

Kloppenburg M, Kroon FP, Blanco FJ, Doherty M, Dziedzic KS, Greibrokk E, Haugen IK, Herrero-Beaumont G, Jonsson H, Kjeken I, Maheu E, Ramonda R, Ritt MJ, Smeets W, Smolen JS, Stamm TA, Szekanecz Z, Wittoek R, Carmona L.

Ann Rheum Dis. 2019 Jan;78(1):16-24. doi: 10.1136/annrheumdis-2018-213826. Epub 2018 Aug 28.

PMID:
30154087
11.

Editorial: Comorbidity Burden in Rheumatic Diseases.

Nikiphorou E, Nurmohamed MT, Szekanecz Z.

Front Med (Lausanne). 2018 Jul 3;5:197. doi: 10.3389/fmed.2018.00197. eCollection 2018. No abstract available.

12.

Corneal Manifestations of Systemic Sclerosis.

Nagy A, Rentka A, Nemeth G, Ziad H, Szücs G, Szekanecz Z, Gesztelyi R, Zsuga J, Aszalos Z, Szodoray P, Kemeny-Beke A.

Ocul Immunol Inflamm. 2018 Jul 17:1-10. doi: 10.1080/09273948.2018.1489556. [Epub ahead of print]

PMID:
30015530
13.

Impact of obesity on autoimmune arthritis and its cardiovascular complications.

Van Raemdonck K, Umar S, Szekanecz Z, Zomorrodi RK, Shahrara S.

Autoimmun Rev. 2018 Aug;17(8):821-835. doi: 10.1016/j.autrev.2018.02.007. Epub 2018 Jun 6. Review.

PMID:
29885537
14.

Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis.

Balogh E, Veale DJ, McGarry T, Orr C, Szekanecz Z, Ng CT, Fearon U, Biniecka M.

Arthritis Res Ther. 2018 May 29;20(1):95. doi: 10.1186/s13075-018-1592-1.

15.

Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment.

Diószegi Á, Tarr T, Nagy-Vincze M, Nánásy-Vass M, Veisz R, Bidiga L, Dezső B, Balla J, Szodoray P, Szekanecz Z, Soltész P.

Lupus. 2018 Aug;27(9):1552-1558. doi: 10.1177/0961203318768890. Epub 2018 Apr 10.

PMID:
29635999
16.

The Impact of Drug Metabolism Gene Polymorphisms on Therapeutic Response and Survival in Diffuse Large B-Cell Lymphoma Patients.

Pál I, Illés Á, Gergely L, Pál T, Radnay Z, Szekanecz Z, Zilahi E, Váróczy L.

Isr Med Assoc J. 2018 Apr;20(4):217-221.

17.

Laser-induced plasma spectroscopy (LIPS): use of a geological tool in assessing bone mineral content.

Andrássy L, Gomez I, Horváth Á, Gulyás K, Pethö Z, Juhász B, Bhattoa HP, Szekanecz Z.

Lasers Med Sci. 2018 Aug;33(6):1225-1236. doi: 10.1007/s10103-018-2462-4. Epub 2018 Feb 17.

PMID:
29453616
18.

Increased frequency of temporal acoustic window failure in rheumatoid arthritis: a manifestation of altered bone metabolism?

Kardos Z, Oláh C, Sepsi M, Sas A, Kostyál L, Bóta T, Bhattoa HP, Hodosi K, Kerekes G, Tamási L, Bereczki D, Szekanecz Z.

Clin Rheumatol. 2018 May;37(5):1183-1188. doi: 10.1007/s10067-018-4003-8. Epub 2018 Jan 30.

PMID:
29383454
19.

Posterior Reversible Encephalopathy Syndrome (PRES) Associated with Thrombotic Thrombocytopenic Purpura in a Systemic Lupus Erythematosus Patient.

Szamosi S, Bodnár N, Brugós B, Hortobágyi T, Méhes G, Szabó Z, Végh E, Horváth Á, Szekanecz Z, Szűcs A, Szűcs G.

Isr Med Assoc J. 2017 Nov;19(11):700-702. No abstract available.

20.

Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis.

Pál I, Szamosi S, Hodosi K, Szekanecz Z, Váróczy L.

RMD Open. 2017 Nov 1;3(2):e000485. doi: 10.1136/rmdopen-2017-000485. eCollection 2017.

Supplemental Content

Loading ...
Support Center